Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Cellink in a directed new issue of shares of MSEK 100
Mandate

Vinge has advised Cellink in a directed new issue of shares of MSEK 100

June 05, 2018 Capital Markets and Public M&A

Vinge has advised Cellink AB (publ) in connection with a directed new issue of shares to Swedish and internationally well-reputed investors such as the Swedish Fourth AP Fund (AP4), Carl Bennet AB, Claes Dinkelspiel and Handelsbanken Fonder.

The subscription price in the amount of SEK 132.50 has been determined through a so called accelerate bookbuilding procedure. As a result of the new issue, Cellink will receive approximately MSEK 100. The proceeds generated by the new issue of shares will be used, among other things, in order to perform acquisitions in accordance with Cellink’s growth strategy, continued global expansion and future development of its product portfolio. Carnegie Investment

Bank has acted as financial advisor and sole bookrunner.

Vinge’s team consisted of partner Anders Strid together with, among others, Wibeke Sorling and company assistant Camilla Andersson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025